IMPAX LABORATORIES INC (IPXL) Stock Price & Overview
NASDAQ:IPXL • US45256B1017
Current stock price
The current stock price of IPXL is 18.3 null. Today IPXL is down by 0%. In the past month the price decreased by -3.43%. In the past year, price increased by 38.64%.
IPXL Key Statistics
- Market Cap
- 1.352B
- P/E
- 29.05
- Fwd P/E
- 15.38
- EPS (TTM)
- 0.63
- Dividend Yield
- N/A
IPXL Stock Performance
IPXL Stock Chart
IPXL Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to IPXL. When comparing the yearly performance of all stocks, IPXL is one of the better performing stocks in the market, outperforming 79.03% of all stocks.
IPXL Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IPXL. While IPXL is still in line with the averages on profitability rating, there are concerns on its financial health.
IPXL Earnings
IPXL Forecast & Estimates
IPXL Financial Highlights
Over the last trailing twelve months IPXL reported a non-GAAP Earnings per Share(EPS) of 0.63. The EPS decreased by -45.69% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -60.49% | ||
| ROA | -34.73% | ||
| ROE | -250.69% | ||
| Debt/Equity | 4.11 |
IPXL Ownership
About IPXL
Company Profile
Impax Laboratories, Inc. is a technology-based, specialty pharmaceutical company engaged in the development, manufacture, and marketing of specialty prescription pharmaceutical products utilizing its own formulation expertise and drug delivery technologies. IMPAX Laboratories is focusing on two key areas, namely Generic Pharmaceutical Products and Branded Pharmaceutical Products. In the generic pharmaceuticals market, it focuses its efforts on controlled-release generic versions of selected brand-name pharmaceuticals covering a range of therapeutic areas. In the brand-name pharmaceuticals market, Impax is developing products for the treatment of central nervous system disorders. The company sells its products to large pharmaceutical wholesalers, warehousing chain drug stores, mass merchandisers, and mail-order pharmacies through strategic alliances and the company's global pharmaceuticals division.
Company Info
IMPAX LABORATORIES INC
30831 HUNTWOOD AVENUE
HAYWARD CA 94544
CEO: Paul M. Bisaro
Phone: 510-476-2000
IMPAX LABORATORIES INC / IPXL FAQ
What does IMPAX LABORATORIES INC do?
Impax Laboratories, Inc. is a technology-based, specialty pharmaceutical company engaged in the development, manufacture, and marketing of specialty prescription pharmaceutical products utilizing its own formulation expertise and drug delivery technologies. IMPAX Laboratories is focusing on two key areas, namely Generic Pharmaceutical Products and Branded Pharmaceutical Products. In the generic pharmaceuticals market, it focuses its efforts on controlled-release generic versions of selected brand-name pharmaceuticals covering a range of therapeutic areas. In the brand-name pharmaceuticals market, Impax is developing products for the treatment of central nervous system disorders. The company sells its products to large pharmaceutical wholesalers, warehousing chain drug stores, mass merchandisers, and mail-order pharmacies through strategic alliances and the company's global pharmaceuticals division.
What is the current price of IPXL stock?
The current stock price of IPXL is 18.3 null.
Does IPXL stock pay dividends?
IPXL does not pay a dividend.
What is the ChartMill rating of IMPAX LABORATORIES INC stock?
IPXL has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the Price/Earnings (PE) ratio of IMPAX LABORATORIES INC (IPXL)?
The PE ratio for IMPAX LABORATORIES INC (IPXL) is 29.05. This is based on the reported non-GAAP earnings per share of 0.63 and the current share price of 18.3 null.